He emphasized that residential investment will be crucial for overall GDP growth, as current CapEx spending in the US is ...

Merck announced ACIP voted to recommend Enflosnia (clesrovimab-cfor) as a treatment option for RSV in infants younger than 8 months of age who are born during or entering their first RSV season.

New data from Biogen reveals higher Spinraza doses may enhance motor function in SMA patients. Read more here.

New analyses from DEVOTE Part C further characterize the improvements in motor function in participants with SMA who transitioned to the investigational higher dose regimen of nusinersen from 12 mg SP ...